Thanks to medical advances, we're living longer lives but with that comes rising rates of Alzheimer's disease. Currently 6 million Americans have Alzheimer's, and that could triple by 2050. This episode explores emerging innovations offering hope against neurodegenerative diseases. We'll discuss promising new drugs that could slow cognitive decline and the strides scientists are making towards understanding causes and developing therapies—and how these breakthroughs are giving hope to one family fighting to save their mom. Episode two explores the history of Alzheimer’s, its current challenges, and the promising therapies made possible by innovation and investment. You’ll hear from: Dr. Asa Abeliovich, Neurologist, Molecular Geneticist, and Founder and CEO at Leal Therapeutics Carl Gordon, Managing Partner and Head of Global Private Equity at OrbiMed Ham Lee, Co-Head of the Healthcare Practice at Cambridge Associates Randi Casciano, Director of Global Public Relations at Cambridge Associates Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related